Sanofi shares positive results from trial of frexalimab for MS

French pharmaceutical company Sanofi has announced positive results from a Phase II trial of its investigational anti-CD40L antibody, frexalimab.

In the trial, the drug was found to reduce brain lesions in patients with relapsing multiple sclerosis (MS).